Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

Opinion|Videos|February 18, 2025

Navigating The Future of NMIBC Trails: Key Insights and Takeaways

Experts conclude their discussion on non-muscle invasive bladder cancer (NMIBC) highlighting practice considerations for today and the future.

Episodes in this series

EP. 1 A Comprehensive Overview of NMIBC

EP. 1 A Comprehensive Overview of NMIBC

EP. 2 Standard of Care: Staging Considerations and Establishing Patient-Provider Relationships

EP. 2 Standard of Care: Staging Considerations and Establishing Patient-Provider Relationships

EP. 3 Navigating Therapies for BCG-Unresponsive NMIBC: Immunotherapies and Chemotherapies

EP. 3 Navigating Therapies for BCG-Unresponsive NMIBC: Immunotherapies and Chemotherapies

EP. 4 New Horizons in NMIBC: Pipeline Innovations and Clinical Perspectives

EP. 4 New Horizons in NMIBC: Pipeline Innovations and Clinical Perspectives

EP. 5 Reducing Recurrence in NMIBC and Novel Treatment Approaches on the Horizon

EP. 5 Reducing Recurrence in NMIBC and Novel Treatment Approaches on the Horizon

EP. 6 Practical Patient-Centered Logistics: Providing Care to Patients With NMIBC

EP. 6 Practical Patient-Centered Logistics: Providing Care to Patients With NMIBC

EP. 7 The Mental Health Impact of NMIBC Treatment: Management With Your Patient

EP. 7 The Mental Health Impact of NMIBC Treatment: Management With Your Patient

EP. 8 Navigating The Future of NMIBC Trails: Key Insights and Takeaways

EP. 8 Navigating The Future of NMIBC Trails: Key Insights and Takeaways

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Treatment Patterns in Advanced Prostate Cancer from Monotherapy to Treatment Intensification

ByPaul Sieber, MD,Alicia Morgans, MD, MPH,Chad Ritch, MD, MBA,Neeraj Agarwal, MD, FASCO

February 4th 2026

Interpreting PSMA PET Imaging in Prostate Cancer

ByPaul Sieber, MD,Alicia Morgans, MD, MPH,Chad Ritch, MD, MBA,Neeraj Agarwal, MD, FASCO

February 4th 2026

Strategic Use of ADT in mCSPC From Selection to Escalation

ByPaul Sieber, MD,Alicia Morgans, MD, MPH,Chad Ritch, MD, MBA,Neeraj Agarwal, MD, FASCO

January 27th 2026

Treatment Selection in Advanced Prostate Cancer

ByPaul Sieber, MD,Alicia Morgans, MD, MPH,Chad Ritch, MD, MBA,Neeraj Agarwal, MD, FASCO

January 27th 2026

Advice for the Next Generation of Urologists in mCSPC Management

ByDavid Morris, MD, FACS,Daniel Saltzstein, MD,Stephen J. Freedland, MD,Tim A. Richardson, MD

January 27th 2026

Latest CME

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

February 23, 2026

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Trending on Urology Times

FDA approves sildenafil oral film for men with erectile dysfunction

The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD

Head-to-head analysis shows OS benefit with apalutamide vs darolutamide in mCSPC

Phase 1/2 trial launches of molecular glue degrader for ccRCC

URO-1 prostate biopsy devices adopted across Novant Health System as clinical study continues